Skip to main content
Journal cover image

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.

Publication ,  Journal Article
Vrooman, LM; Supko, JG; Neuberg, DS; Asselin, BL; Athale, UH; Clavell, L; Kelly, KM; Laverdière, C; Michon, B; Schorin, M; Cohen, HJ ...
Published in: Pediatr Blood Cancer
February 2010

BACKGROUND: Escherichia coli asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia (ALL); however, hypersensitivity develops in up to 30% of patients. We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase, an alternative preparation, in E. coli asparaginase-allergic patients. PATIENTS AND METHODS: Between 2000 and 2002, 215 children with newly diagnosed ALL were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 and were to receive 30 weekly doses of intramuscular E. coli asparaginase. If E. coli asparaginase allergy developed, patients were switched to twice-weekly intramuscular Erwinia asparaginase (25,000 IU/m(2)). Nadir serum asparaginase activity (NSAA) was measured every 3 weeks. RESULTS: Forty-two patients (20%) developed E. coli asparaginase allergy and switched to Erwinia. Of 38 patients with evaluable samples, 34 (89%) Erwinia-treated patients had at least one therapeutic NSAA (> or =0.1 IU/ml). The median NSAA was 0.247 IU/ml 3 days and 0.077 IU/ml 4 days after an Erwinia dose. Associated toxicities included allergy in 14 (33%) and pancreatitis in 3 patients (7%). At a median follow-up of 5.4 years, event-free survival (+/-standard error) of the 42 patients who switched to Erwinia was 86 +/- 5% compared with 81 +/- 3% for the 170 patients without E. coli asparaginase allergy (P = 0.55). CONCLUSIONS: Twice-weekly Erwinia asparaginase was well tolerated and achieved a therapeutically effective NSAA in most E. coli asparaginase-allergic patients. Development of E. coli allergy and subsequent treatment with twice-weekly Erwinia did not adversely impact event-free survival. Erwinia asparaginase should be considered for E. coli asparaginase-allergic patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

February 2010

Volume

54

Issue

2

Start / End Page

199 / 205

Location

United States

Related Subject Headings

  • Survival Analysis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Infant
  • Humans
  • Escherichia coli
  • Erwinia
  • Drug Hypersensitivity
  • Drug Administration Schedule
  • Child, Preschool
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vrooman, L. M., Supko, J. G., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L., … Silverman, L. B. (2010). Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer, 54(2), 199–205. https://doi.org/10.1002/pbc.22225
Vrooman, Lynda M., Jeffrey G. Supko, Donna S. Neuberg, Barbara L. Asselin, Uma H. Athale, Luis Clavell, Kara M. Kelly, et al. “Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.Pediatr Blood Cancer 54, no. 2 (February 2010): 199–205. https://doi.org/10.1002/pbc.22225.
Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb;54(2):199–205.
Vrooman, Lynda M., et al. “Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.Pediatr Blood Cancer, vol. 54, no. 2, Feb. 2010, pp. 199–205. Pubmed, doi:10.1002/pbc.22225.
Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb;54(2):199–205.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

February 2010

Volume

54

Issue

2

Start / End Page

199 / 205

Location

United States

Related Subject Headings

  • Survival Analysis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Infant
  • Humans
  • Escherichia coli
  • Erwinia
  • Drug Hypersensitivity
  • Drug Administration Schedule
  • Child, Preschool